About Sodium channel regulatory subunit beta-1
Sodium channel regulatory subunit beta-1 (SCN1B) is a protein
from Homo sapiens identified by UniProt accession
Q07699, 218 residues long.
MolForge cross-references it against 0 known binders and
259 disease associations.
Target properties
| Protein name | Sodium channel regulatory subunit beta-1 |
| UniProt accession | Q07699 |
| Gene | SCN1B |
| Organism | Homo sapiens |
| Length | 218 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (259)
Diseases linked to this target (Open Targets).
- Generalized epilepsy with febrile seizures-plus · score 0.75
- developmental and epileptic encephalopathy, 52 · score 0.73
- Brugada syndrome · score 0.73
- developmental and epileptic encephalopathy · score 0.68
- familial atrial fibrillation · score 0.64
- Abnormality of the cardiovascular system · score 0.47
- Dravet syndrome · score 0.46
- generalized epilepsy with febrile seizures plus · score 0.45
- cardiac conduction defect · score 0.44
- conduction system disorder · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q07699-F1 | alphafold | PREDICTED | 87.09 | — |
Amino-acid sequence (218 residues)
MGRLLALVVG AALVSSACGG CVEVDSETEA VYGMTFKILC ISCKRRSETN AETFTEWTFR QKGTEEFVKI LRYENEVLQL EEDERFEGRV VWNGSRGTKD LQDLSIFITN VTYNHSGDYE CHVYRLLFFE NYEHNTSVVK KIHIEVVDKA NRDMASIVSE IMMYVLIVVL TIWLVAEMIY CYKKIAAATE TAAQENASEY LAITSESKEN CTGVQVAE
Explore Sodium channel regulatory subunit beta-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets